Aardvark menghentikan sementara uji coba Fase 3 HERO ARD-101 pada PWS

Perusahaan secara sukarela menghentikan sementara pendaftaran dan pemberian dosis dalam uji coba Fase 3 HERO dan OLE ARD-101 setelah temuan jantung yang dapat pulih dalam studi relawan sehat. Perusahaan sedang bekerja sama dengan FDA untuk menentukan langkah selanjutnya dan mengharapkan memberikan panduan lebih lanjut pada Q2 2026. Pengembangan ARD-201 juga dihentikan sementara.

Fakta utama

Diajukan: 7 Mei 2026, 13.28
Peristiwa: Perubahan registri uji klinis
Arah: Negatif
Perusahaan: AARDAardvark Therapeutics
Aset: ARD-101
Sumber: SEC 8-K
Keyakinan: Bersumber

Kutipan sumber

EX-99.1 2 ck0001774857-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates.

SEC 8-K